Bionano Return On Capital Employed from 2010 to 2024

BNGO Stock  USD 0.24  0.01  4.00%   
Bionano Genomics Return On Capital Employed yearly trend continues to be very stable with very little volatility. Return On Capital Employed is likely to drop to -1.98. During the period from 2010 to 2024, Bionano Genomics Return On Capital Employed quarterly data regression pattern had sample variance of  5.92 and median of (3.90). View All Fundamentals
 
Return On Capital Employed  
First Reported
2010-12-31
Previous Quarter
(1.88)
Current Value
(1.98)
Quarterly Volatility
2.43239491
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bionano Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bionano Genomics' main balance sheet or income statement drivers, such as Tax Provision of 65.1 K, Interest Income of 3.5 M or Depreciation And Amortization of 14.4 M, as well as many indicators such as Price To Sales Ratio of 1.7, Dividend Yield of 0.0 or PTB Ratio of 0.64. Bionano financial statements analysis is a perfect complement when working with Bionano Genomics Valuation or Volatility modules.
  
Check out the analysis of Bionano Genomics Correlation against competitors.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Latest Bionano Genomics' Return On Capital Employed Growth Pattern

Below is the plot of the Return On Capital Employed of Bionano Genomics over the last few years. It is Bionano Genomics' Return On Capital Employed historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bionano Genomics' overall financial position and show how it may be relating to other accounts over time.
Return On Capital Employed10 Years Trend
Slightly volatile
   Return On Capital Employed   
       Timeline  

Bionano Return On Capital Employed Regression Statistics

Arithmetic Mean(2.45)
Geometric Mean2.15
Coefficient Of Variation(99.42)
Mean Deviation1.92
Median(3.90)
Standard Deviation2.43
Sample Variance5.92
Range10.1978
R-Value0.42
Mean Square Error5.23
R-Squared0.18
Significance0.12
Slope0.23
Total Sum of Squares82.83

Bionano Return On Capital Employed History

2024 -1.98
2023 -1.88
2022 -0.48
2021 -0.22
2020 -0.75
2019 -6.63
2018 -1.01

About Bionano Genomics Financial Statements

Bionano Genomics investors utilize fundamental indicators, such as Return On Capital Employed, to predict how Bionano Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Return On Capital Employed(1.88)(1.98)

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Stock

  0.69A Agilent TechnologiesPairCorr
  0.89ME 23Andme HoldingPairCorr
  0.85VALN Valneva SE ADRPairCorr

Moving against Bionano Stock

  0.85DRUG Bright Minds BiosciencesPairCorr
  0.78VCYT VeracytePairCorr
  0.72VERA Vera TherapeuticsPairCorr
  0.53VANI Vivani MedicalPairCorr
  0.48VCEL Vericel Corp OrdPairCorr
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:
Check out the analysis of Bionano Genomics Correlation against competitors.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.30)
Revenue Per Share
0.749
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.33)
Return On Equity
(1.38)
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.